Ascendis sells Japanese rights to Skytrofa and two other hormone drugs for $70M upfront

Ascendis Pharma has pocketed $70 million in exchange for the Japanese rights to the FDA-approved long-acting growth hormone Skytrofa and two other hormone drugs.

Beyond the upfront payment, Teijin Pharma has pledged up to $175 million in development and regulatory milestones as well as additional commercial milestones and royalties that could reach up to the mid-20s per cent.